Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), We would like to inform ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 1.0 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eiko Lifesciences' board approved audited standalone and consolidated financial results for Q4 and FY ended 31 March 2025, along with an unmodified auditor's opinion from PSV Jain & Associates. On a standalone basis, FY25 revenue from operations rose to ₹3,249.18 lakhs from ₹2,792.93 lakhs in FY24, while profit after tax jumped to ₹174.08 lakhs from ₹75.15 lakhs, a growth of about 132%. Consolidated FY25 revenue stood at ₹3,766.40 lakhs with PAT of ₹231.86 lakhs and EPS of ₹1.62. This is the first year of consolidated reporting since the logistics subsidiary commenced operations. The board also appointed M/s Shravan Gupta & Associates as Secretarial Auditor for 5 years and M/s NP Rajput & Co as Internal Auditor for FY26. An exceptional item of ₹34.12 lakhs was recorded, representing interest from shareholders on delayed call money payments.
Strong profit growth and a clean audit opinion are positives for shareholders, but the negative operating cash flow in both standalone (-₹205 lakhs) and consolidated (-₹292 lakhs) suggests working capital pressures despite the earnings improvement. Investors should watch how the new logistics segment contributes and whether cash generation improves.